NCT02721459 2026-03-02XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV MelanomaH. Lee Moffitt Cancer Center and Research InstitutePhase 1 Active not recruiting26 enrolled
NCT04835805 2026-02-03A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Genentech, Inc.Phase 1 Active not recruiting65 enrolled
NCT03181100 2026-01-09Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid CancerM.D. Anderson Cancer CenterPhase 2 Active not recruiting50 enrolled